Edward, Justin A.
Josey, Kevin
Bahn, Gideon
Caplan, Liron
Reusch, Jane E. B.
Reaven, Peter
Ghosh, Debashis
Raghavan, Sridharan
Funding for this research was provided by:
Cooperative Studies Program (465-F)
National Science Foundation (DMS 1914937)
National Cancer Institute of the US National Institutes of Health (R01 CA129102)
U.S. Department of Veterans Affairs (IK2-CX001907)
Article History
Received: 10 March 2022
Accepted: 31 March 2022
First Online: 27 April 2022
Declarations
:
: Not applicable.
: Not applicable.
: The authors have no conflicts of interest relevant to the work in this study. Medications and financial support were provided by Sanofi, GlaxoSmithKline, Novo Nordisk, Roche, Kos Pharmaceuticals, Merck, and Amylin. No other potential conflicts of interest relevant to this article were reported. These companies had no role in the design of the study, in the accrual or analysis of the data, or in the preparation or approval of the manuscript.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the US Department of Veterans Affairs.
: All of the contributing investigators to the Veterans Affairs Diabetes Trial are acknowledged in a document for publication as an online-only supplement.